Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$502.12 13.79 (2.67)%
Market Cap 52.41B
06/27/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Goldman Sachs 38th Annual Global Healthcare Conference
Jun 13, 2017 | 11:40 AM ET
Regeneron Corporate Presentation June 2017
Jun 13, 2017